Myron Czuczman - Aug 12, 2024 Form 4/A - Amendment Insider Report for CITIUS ONCOLOGY, INC. (CTOR)

Role: Chief Medical Officer
Signature: /s/ Lorna A. Knick, by Power of Attorney
Stock symbol: CTOR
Transactions as of: Aug 12, 2024
Transactions value $: $0
Form type: 4/A - Amendment
Date filed: 8/30/2024, 04:05 PM
Date Of Original Report: Aug 14, 2024
Previous filing: Oct 12, 2023
Next filing: Nov 12, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CTOR	Stock Option (Right to Buy)	Award	$0	+1.4M		$0.00	1.4M	Aug 12, 2024	Common Stock	1.4M	$2.15	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This option, originally issued by Citius Oncology Sub, Inc., vests over three years, beginning July 5, 2023, with 1/36th every month for the first year, and the 1/3 each on the second and third anniversary of the July 5, 2023, provided that the Reporting Person provides continuous services to Citius Oncology Sub, Inc. or a related entity as of each such vesting date. The option was assumed by Citius Oncology, Inc. in the merger transaction, which closed August 12, 2024.
F2	This Form 4 has been amended to correct the amount of option shares held by the Reporting Person.

Content

This option, originally issued by Citius Oncology Sub, Inc., vests over three years, beginning July 5, 2023, with 1/36th every month for the first year, and the 1/3 each on the second and third anniversary of the July 5, 2023, provided that the Reporting Person provides continuous services to Citius Oncology Sub, Inc. or a related entity as of each such vesting date. The option was assumed by Citius Oncology, Inc. in the merger transaction, which closed August 12, 2024.

This Form 4 has been amended to correct the amount of option shares held by the Reporting Person.